Translating neuroscientific, neurological, and psychiatric research into effective therapies remains a major challenge for both academic researchers and industry experts. This open access volume reviews the progress achieved over the past decade and provides an outlook on emerging concepts, technologies, and diverse therapeutic modalities. 

The book brings together leading experts to review and discuss the current state of translational neuroscience, spanning recent discoveries in the underlying mechanisms, cutting‑edge technologies, advances in therapeutic development, and the application of artificial intelligence. The first section focuses on key challenges in translational psychiatry, with dedicated chapters on autism spectrum disorder, bipolar disorder, and novel treatment approaches, including neuromodulation and psychedelics, as well as an overview of patient stratification strategies in psychiatry. Additional chapters provide a comprehensive review of translating research in Alzheimer’s disease and Parkinson’s disease into the clinics. The volume concludes with an extensive section highlighting innovative strategies, novel model systems, and AI‑based approaches to advance translational research for neurological disorders.

This up‑to‑date reference not only summarizes the current understanding and therapeutic landscape for major neurodegenerative and neuropsychiatric diseases but also highlights future directions and emerging opportunities in translational neuroscience. We expect that it will encourage others to embark on the arduous but rewarding path towards new medicines and therapies for patients with neurological or psychiatric conditions.

“A rather comprehensive volume on recent advances in translational neuroscience that have (and will) meaningfully impact on the treatment landscape for the major neuropsychiatric disorders. The authors have done a masterful job at bridging recent basic neuroscience findings as they apply to fundamental disease biology, identifying both gaps in current knowledge and major advances …. and nicely capturing how such information is being effectively “translated“ to new and improved and more “precise“ treatments  The volume is both sobering and inspiring, underscoring the challenges and opportunities of this important scientific discipline, and is a must read for those interested in better understanding some of the most common and disabling of all brain disorders”. Steve Paul, MD Washington University of St. Louis School of Medicine.

“This book offers a comprehensive and engaging account of modern translational neuroscience, spanning molecular mechanisms to therapeutic possibilities, with a rare breadth across psychiatric and neurodegenerative disorders”. Tony Wyss-Coray, PhD, Stanford University.

“This is an interdisciplinary, timely and inspiring book, a thoughtful synthesis by the authors. As they describe with compassion and compelling examples, brain disorders that emerge during childhood or aging pose formidable personal, medical and socioeconomic problems. Fortunately, as also effectively highlighted in this book, there is good reason for hope: new insights into disease mechanisms are being gained at an unprecedented pace, and several of those insights will likely enable the development of better therapeutic strategies, which are awaited so very urgently by patients, families and physicians alike”. Lennart Mucke, MD, University of California.

Karoly Nikolich
Karoly Nikolich, PhD is an adjunct professor in the Department of Psychiatry and Behavioral Sciences at Stanford University. He is also an advisor and former partner with Pivotal Life Sciences, and with Grifols, a global plasma therapeutics company and owner and director of the Schaller-Nikolich Foundation. Nikolich also serves as a board member of the Chica and Heinz Schaller Foundation, based in Heidelberg, Germany.

After graduating from Eötvös Loránd University in Budapest, Hungary, he worked as postdoctoral fellow at Tulane University School of Medicine, and as a research scientist at Semmelweis University and at the University of California, San Francisco. During the 1980s and early 1990s, he led Genentech’s entry into neuroscience and led and participated in the development of numerous protein therapeutics. From 1995 to 1997 he was vice president of research at Lynx Therapeutics, a pioneering DNA sequencing company founded by Sydney Brenner (acquired by Illumina). In 1998, Nikolich co-founded AGY Therapeutics with Bob Swanson, founder of Genentech. Between 2005 and 2007, he was executive director of the Neuroscience Institute at Stanford University. He later founded several companies, including Amnestix, NeuroFluidics, and Chase Pharmaceuticals, all of which were successfully acquired. In 2010, he founded Circuit Therapeutics (now MapLight Therapeutics), and in 2014, Alkahest (acquired by Grifols). Nikolich also co-founded Neuropore Therapies, Hummingbird Diagnostics, Chase Therapeutics, NeuroTherapia, Addition Therapeutics and Engrail Therapeutics, and he has served as board chair or board member at these companies. Since the acquisition of Alkahest by Grifols in 2021, he has served as executive innovation advisor supporting a program based on the largest longitudinal plasma collection for biomarker and therapeutic target discovery. His four decade career has focused on translating neuroscientific discoveries into therapies.

He published over 140 papers and chapters cited over 13,000 times covering protein therapeutics, neurotrophic factors, neurodegenerative and neuroprotective mechanisms. He also served as an advisor for several investment funds, family offices and foundations. In 2014, he organized and co-chaired with Steve Hyman the first Translational Neuroscience conference in Frankfurt, Germany, supported by the Ernst Strüngmann Forum. In 2024, Karoly Nikolich and Robert Malenka organized and co-chaired the second Translational Neuroscience conference in California.

Robert C. Malenka
Robert C. Malenka, MD, PhD, is the Pritzker Professor of Psychiatry and Behavioral Sciences, Director of the Nancy Pritzker Laboratory and a founder of Stanford University’s Wu Tsai Neurosciences Institute for which he was Deputy Director for 10 years. After graduating from Harvard College (Summa cum laude, phi beta kappa) he received an M.D. and a Ph.D. in neuroscience in 1983 from Stanford University School of Medicine. Over the ensuing 6 years he completed residency training in psychiatry at Stanford and 4 years of postdoctoral research at the University of California, San Francisco (UCSF). In 1989, he was appointed Assistant Professor of Psychiatry and Physiology at UCSF, at which he reached the rank of Full Professor in 1996. He returned to the Stanford University School of Medicine in 1999.

He is an elected member of the United States’ National Academy of Sciences and the National Academy of Medicine as well as an elected fellow of the American Academy of Arts and Sciences, the American Association for the Advancement of Science, and the American College of Neuropsychopharmacology. He has served on the National Advisory Council on Drug Abuse and as a Councilor for the Society for Neuroscience and the American College of Neuropsychopharmacology. He has served on the scientific advisory boards of numerous non-profit foundations, biotechs and pharma. His honorary awards include: the Society for Neuroscience Young Investigator Award (1993); the Daniel Efron Award from the American College of Neuropsychopharmacolgoy (1998); the Kemali Foundation International Prize in Neuroscience (2000); the CINP-Lilly Neuroscience Basic Research Award (2002), the Perl/UNC Neuroscience Prize (2006), the ARSAD Goldman-Rakic Prize for Outstanding Neuroscience Research (2010), the Pasarow Foundation Award for Extraordinary Accomplishment in Neuropsychiatry Research (2011), and the Society for Neuroscience Julius Axelrod Prize (2016) and Peter Seeburg Integrative Neuroscience Prize (2022).

His papers have been cited >130,000 times and have provided foundational knowledge about the mechanisms of synaptic plasticity and neuromodulation in the mammalian brain. His laboratory continues to conduct research on the synaptic and circuit mechanisms that mediate motivated behaviors of relevance to a range of brain disorders including addiction, autism, and depression. He helped organize the prior Translational Neuroscience conference in Frankfurt, Germany supported by the Ernst Strungmann Forum. In 2024, he organized and co-chaired with Karoly Nikolich the Translational Neuroscience 2.0 conference in California.